These results underscore the robust clinical predictive performance of our four-gene signature (MAOB, IGFBP2, SERPINA1, and LGR6), establishing its capacity to independently prognosticate outcomes in cases with grade II/III gliomas, even after adjusting for age, grade stage, and IDH mutation status. The gene discussed is IGFBP2; the disease is glioma.